口服硼替佐米 MRX-5 在小鼠中显示出对肺部的疗效。
Oral oxaborole MRX-5 exhibits efficacy against pulmonary in mouse.
机构信息
Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
MicuRx Pharmaceuticals, Inc., Foster City, California, USA.
出版信息
Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0135124. doi: 10.1128/aac.01351-24. Epub 2024 Oct 3.
) is an opportunistic pathogen common in patients with lung comorbidities and immunosuppression. There are no FDA-approved treatments, and current treatment has a failure rate exceeding 50%. The intravenous oxaborole MRX-6038 is active against . This study evaluated MRX-5, the oral prodrug, against five isolates in a mouse lung infection model. MRX-5 showed dose-dependent efficacy, with 15 and 45 mg/kg doses comparable to the standard of care, supporting progression to clinical trial.
是一种机会性病原体，常见于肺部合并症和免疫抑制的患者。目前尚无 FDA 批准的治疗方法，且现有治疗方法的失败率超过 50%。静脉注射硼替佐米类药物 MRX-6038 对具有活性。本研究评估了口服前药 MRX-5 在小鼠肺部感染模型中对五种 分离株的疗效。MRX-5 表现出剂量依赖性疗效，15 和 45mg/kg 剂量与标准治疗相当，支持进入临床试验。
Zotero 插件